1. Medtech Insight
  2. >>Policy & Regulation

Medicare Payment Roundup: Pass-Through Reforms, Packaging And More

Key device updates in CMS's latest payment rules include reforms to the hospital outpatient pass-through payment process for new technology, the agency's continued march forward on "comprehensive" outpatient procedure payments, scaled-back physician cuts for radiation oncology and reimbursement for transoral GERD procedures.

Health care providers and product manufacturers are poring over CMS' recently released 2016 payment system rules. Here are a few key takeaways for device companies from the Medicare hospital outpatient prospective payment system and physician fee schedule final rules.

CMS decisions on awarding bonus hospital outpatient "pass-through" payments to new technology will be subject to a stricter "newness" standard starting next year, and to a rulemaking process. That is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.